Zelnecirnon: A CCR4 INHIBITOR THAT MODULATES THE IMMUNE RESPONSE IN INFLAMMATORY DISORDERS

Explore how zelnecirnon (RPT193)—designed to block CCR4—may potentially impact inflammatory disorders including eczema (atopic dermatitis) and asthma.

How PRT193 works
Zelnecirnon is currently being evaluated in eczema and asthma clinical trials.

Zelnecirnon is an orally-administered small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in a broad range of inflammatory disorders. Although there are existing injectable and oral treatments for eczema, we believe there remains an unmet need for a safe, highly effective oral treatment.

We have completed a randomized, placebo-controlled, Phase 1b trial in patients with eczema, in which patients treated with zelnecirnon showed clear improvement in several key exploratory endpoints and the drug was well tolerated and showed a favorable safety profile. These early data suggest that this novel mechanism of action targeting CCR4 on Th2 cells may provide an alternative to existing injectable and oral treatments.